Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes

Ítems similars

• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  per: Sehgal, Kartik, et al.
  Publicat: (2020)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  per: Rangachari, Deepa, et al.
  Publicat: (2017)
• Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice
  per: Rangachari, Deepa, et al.
  Publicat: (2016)
• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  per: Vasconcelos, Pedro E.N.S., et al.
  Publicat: (2020)
• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  per: Jorge, Susan E., et al.
  Publicat: (2015)